Enzon Pharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 2/6
Enzon Pharmaceuticals's earnings have been declining at an average annual rate of -26.3%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 86.2% per year. Enzon Pharmaceuticals's return on equity is 3.4%, and it has net margins of 1207.7%.
Información clave
-26.3%
Tasa de crecimiento de los beneficios
-31.4%
Tasa de crecimiento del BPA
Crecimiento de la industria Biotechs | 17.0% |
Tasa de crecimiento de los ingresos | -86.2% |
Rentabilidad financiera | 3.4% |
Margen neto | 1,207.7% |
Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
No hay actualizaciones
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Enzon Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
30 Jun 24 | 0 | 0 | 1 | 0 |
31 Mar 24 | 0 | 0 | 1 | 0 |
31 Dec 23 | 0 | 0 | 1 | 0 |
30 Sep 23 | 0 | 0 | 1 | 0 |
30 Jun 23 | 0 | -1 | 1 | 0 |
31 Mar 23 | 0 | -1 | 1 | 0 |
31 Dec 22 | 0 | -1 | 1 | 0 |
30 Sep 22 | 0 | -3 | 1 | 0 |
30 Jun 22 | 0 | -3 | 1 | 0 |
31 Mar 22 | 0 | -3 | 1 | 0 |
31 Dec 21 | 1 | -2 | 1 | 0 |
30 Sep 21 | 1 | -3 | 1 | 0 |
30 Jun 21 | 1 | -2 | 2 | 0 |
31 Mar 21 | 0 | -2 | 1 | 0 |
31 Dec 20 | 0 | -2 | 1 | 0 |
30 Sep 20 | 0 | -1 | 1 | 0 |
30 Jun 20 | 0 | -1 | 1 | 0 |
31 Mar 20 | 0 | -1 | 1 | 0 |
31 Dec 19 | 0 | -1 | 1 | 0 |
30 Sep 19 | 7 | 6 | 1 | 0 |
30 Jun 19 | 7 | 6 | 1 | 0 |
31 Mar 19 | 7 | 6 | 1 | 0 |
31 Dec 18 | 7 | 6 | 1 | 0 |
30 Sep 18 | 0 | -1 | 1 | 0 |
30 Jun 18 | 0 | 0 | 1 | 0 |
31 Mar 18 | 7 | 4 | 1 | 0 |
31 Dec 17 | 8 | 5 | 1 | 0 |
30 Sep 17 | 9 | 0 | 1 | 0 |
30 Jun 17 | 11 | 1 | 1 | 0 |
31 Mar 17 | 7 | -2 | 1 | 0 |
31 Dec 16 | 8 | -1 | 2 | 0 |
30 Sep 16 | 11 | 16 | 2 | 0 |
30 Jun 16 | 12 | 13 | 2 | 0 |
31 Mar 16 | 15 | 16 | 2 | 0 |
31 Dec 15 | 17 | 22 | 2 | 0 |
30 Sep 15 | 20 | 15 | 1 | 0 |
30 Jun 15 | 25 | 24 | 2 | 0 |
31 Mar 15 | 27 | 27 | 2 | 0 |
31 Dec 14 | 31 | 29 | 2 | 0 |
30 Sep 14 | 32 | 28 | 4 | 0 |
30 Jun 14 | 33 | 26 | 5 | 1 |
31 Mar 14 | 33 | 24 | 6 | 1 |
31 Dec 13 | 34 | 18 | 9 | 3 |
Ingresos de calidad: ENZN has high quality earnings.
Margen de beneficios creciente: ENZN became profitable in the past.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: ENZN's earnings have declined by 26.3% per year over the past 5 years.
Acelerando crecimiento: ENZN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Beneficios vs. Industria: ENZN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rentabilidad financiera
Alta ROE: ENZN's Return on Equity (3.4%) is considered low.